Marc Buyse
Marc Buyse
Chief Scientific Officer, IDDI
Verified email at iddi.com - Homepage
Title
Cited by
Cited by
Year
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
C Tournigand, T André, E Achille, G Lledo, M Flesh, D Mery-Mignard, ...
Journal of Clinical Oncology 22 (2), 229-237, 2004
36492004
Adjuvant trastuzumab in HER2-positive breast cancer
D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, M Press, ...
New England journal of medicine 365 (14), 1273-1283, 2011
25482011
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
C Sotiriou, P Wirapati, S Loi, A Harris, S Fox, J Smeds, H Nordgren, ...
Journal of the National Cancer Institute 98 (4), 262-272, 2006
20362006
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 379 (9814), 432-444, 2012
16972012
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
M Buyse, S Loi, L Van't Veer, G Viale, M Delorenzi, AM Glas, ...
Journal of the National Cancer Institute 98 (17), 1183-1192, 2006
13912006
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women …
P McGale, C Correa, D Cutter, F Duane, M Ewertz, R Gray, G Mannu, ...
The Lancet 383 (9935), 2127-35, 2014
12842014
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases
U Pastorino, M Buyse, G Friedel, RJ Ginsberg, P Girard, P Goldstraw, ...
The Journal of thoracic and cardiovascular surgery 113 (1), 37-49, 1997
11661997
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
C Desmedt, F Piette, S Loi, Y Wang, F Lallemand, B Haibe-Kains, G Viale, ...
Clinical cancer research 13 (11), 3207-3214, 2007
10392007
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study
C Tournigand, A Cervantes, A Figer, G Lledo, M Flesch, M Buyse, ...
Journal of clinical oncology 24 (3), 394-400, 2006
9802006
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
M Dowsett, J Cuzick, J Ingle, A Coates, J Forbes, J Bliss, M Buyse, ...
Journal of Clinical Oncology 28 (3), 509-518, 2010
9332010
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer
MEL Van Der Burg, M Van Lent, M Buyse, A Kobierska, N Colombo, ...
New England Journal of Medicine 332 (10), 629-634, 1995
9021995
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
S Loi, B Haibe-Kains, C Desmedt, F Lallemand, AM Tutt, C Gillet, P Ellis, ...
Journal of clinical oncology 25 (10), 1239, 2007
8782007
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
C Desmedt, B Haibe-Kains, P Wirapati, M Buyse, D Larsimont, ...
Clinical cancer research 14 (16), 5158-5165, 2008
8642008
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer
Early Breast Cancer Trialists' Collaborative Group
New England journal of medicine 319 (26), 1681-1692, 1988
8591988
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.
X Paoletti, K Oba, T Burzykowski, S Michiels, Y Ohashi, JP Pignon, ...
Jama 303 (17), 1729-1737, 2010
8402010
Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC).
A Gerard, M Buyse, B Nordlinger, J Loygue, F Pène, P Kempf, JF Bosset, ...
Annals of surgery 208 (5), 606, 1988
8231988
Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab …
DJ Slamon
Breast Cancer Res Treat 94, S5, 2005
732*2005
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
DJ Sargent, HS Wieand, DG Haller, R Gray, JK Benedetti, M Buyse, ...
Journal of Clinical Oncology 23 (34), 8664-8670, 2005
7042005
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials
D Sargent, A Sobrero, A Grothey, MJ O'Connell, M Buyse, T Andre, ...
Journal of Clinical Oncology 27 (6), 872, 2009
5692009
The validation of surrogate endpoints in meta-analyses of randomized experiments
M Buyse, G Molenberghs, T Burzykowski, D Renard, H Geys
Biostatistics 1 (1), 49-67, 2000
5502000
The system can't perform the operation now. Try again later.
Articles 1–20